Literature DB >> 10542134

cbl-b inhibits EGF-receptor-induced apoptosis by enhancing ubiquitination and degradation of activated receptors.

S A Ettenberg1, Y R Rubinstein, P Banerjee, M M Nau, M M Keane, S Lipkowitz.   

Abstract

Studies in C. elegans and Drosophila melanogaster suggest that cbl proteins are inhibitors of epidermal growth factor receptor (EGFR) function. Here we describe that overexpression of cbl-b, a homologue of the c-cbl protooncogene, inhibits EGFR-induced apoptosis in MDA-MB-468 breast cancer cells. Overexpression of cbl-b results in a shortened duration of EGFR activation upon EGF stimulation. This is demonstrated by decreased amounts of phosphorylated EGFR as well as by inhibition of multiple downstream signaling pathways. The inhibition of signaling by cbl-b results from increased ubiquitination and degradation of the activated EGFR. The inhibitory effects of cbl-b overexpression on apoptosis and on EGFR signaling are reversed by blocking proteosomal degradation of the EGFR. These data demonstrate that the mechanism by which cbl-b inhibits EGFR-induced apoptosis is by activation-dependent degradation of the EGFR. They imply that this mechanism may be a general one whereby cbl proteins regulate intracellular signaling.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10542134     DOI: 10.1006/mcbr.1999.0157

Source DB:  PubMed          Journal:  Mol Cell Biol Res Commun        ISSN: 1522-4724


  16 in total

1.  Neuronal Cbl controls biosynthesis of insulin-like peptides in Drosophila melanogaster.

Authors:  Yue Yu; Ying Sun; Shengqi He; Cheng Yan; Liangyou Rui; Wenjun Li; Yong Liu
Journal:  Mol Cell Biol       Date:  2012-07-09       Impact factor: 4.272

Review 2.  RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.

Authors:  Stanley Lipkowitz; Allan M Weissman
Journal:  Nat Rev Cancer       Date:  2011-08-24       Impact factor: 60.716

3.  EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins.

Authors:  G C Davies; P E Ryan; L Rahman; M Zajac-Kaye; S Lipkowitz
Journal:  Oncogene       Date:  2006-05-15       Impact factor: 9.867

4.  Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization.

Authors:  Mirko H H Schmidt; Frank B Furnari; Webster K Cavenee; Oliver Bögler
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-06       Impact factor: 11.205

5.  Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl-SETA/CIN85 complex.

Authors:  Mirko H H Schmidt; Daniela Hoeller; Jiuhong Yu; Frank B Furnari; Webster K Cavenee; Ivan Dikic; Oliver Bögler
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

6.  Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor.

Authors:  Thomas E Reznik; Yingying Sang; Yongxian Ma; Roger Abounader; Eliot M Rosen; Shuli Xia; John Laterra
Journal:  Mol Cancer Res       Date:  2008-01       Impact factor: 5.852

Review 7.  E3 ubiquitin ligase Cbl-b in innate and adaptive immunity.

Authors:  Qingjun Liu; Hong Zhou; Wallace Y Langdon; Jian Zhang
Journal:  Cell Cycle       Date:  2014-05-14       Impact factor: 4.534

8.  A tale of two Cbls: interplay of c-Cbl and Cbl-b in epidermal growth factor receptor downregulation.

Authors:  Steven Pennock; Zhixiang Wang
Journal:  Mol Cell Biol       Date:  2008-03-03       Impact factor: 4.272

9.  Cbl-c ubiquitin ligase activity is increased via the interaction of its RING finger domain with a LIM domain of the paxillin homolog, Hic 5.

Authors:  Philip E Ryan; Stephen C Kales; Rajgopal Yadavalli; Marion M Nau; Han Zhang; Stanley Lipkowitz
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

10.  Ubiquitination of the bacterial inositol phosphatase, SopB, regulates its biological activity at the plasma membrane.

Authors:  Leigh A Knodler; Seth Winfree; Dan Drecktrah; Robin Ireland; Olivia Steele-Mortimer
Journal:  Cell Microbiol       Date:  2009-07-13       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.